Biotricity, Inc.
BTCY
$0.11
$0.00-2.47%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.01% | 16.47% | 19.51% | 18.12% | 14.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.01% | 16.47% | 19.51% | 18.12% | 14.31% |
| Cost of Revenue | -5.47% | -14.24% | -9.42% | -8.64% | -12.98% |
| Gross Profit | 22.57% | 27.08% | 29.99% | 28.57% | 26.43% |
| SG&A Expenses | -21.78% | -18.95% | -21.32% | -28.65% | -25.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.90% | -14.49% | -15.35% | -21.94% | -22.27% |
| Operating Income | 169.06% | 103.04% | 91.85% | 86.23% | 72.26% |
| Income Before Tax | 71.45% | 62.36% | 63.03% | 62.45% | 40.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.45% | 62.36% | 63.03% | 62.45% | 40.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.45% | 62.36% | 63.03% | 62.45% | 40.25% |
| EBIT | 169.06% | 103.04% | 91.85% | 86.23% | 72.26% |
| EBITDA | 169.47% | 103.18% | 91.94% | 86.30% | 72.31% |
| EPS Basic | 83.44% | 83.78% | 86.22% | 86.57% | 58.09% |
| Normalized Basic EPS | 79.07% | 80.93% | 83.42% | 84.46% | 72.74% |
| EPS Diluted | 83.42% | 83.77% | 86.21% | 86.57% | 58.09% |
| Normalized Diluted EPS | 79.07% | 80.93% | 83.42% | 84.46% | 72.74% |
| Average Basic Shares Outstanding | 25.18% | 52.12% | 88.15% | 140.10% | 142.58% |
| Average Diluted Shares Outstanding | 25.18% | 52.12% | 88.15% | 140.10% | 142.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.80% | -1.68% | -1.70% | -1.66% | -1.80% |